

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
WO 03/059330 A1

(51) International Patent Classification⁷: **A61K 9/24**,
38/55, 31/401

(21) International Application Number: PCT/IB03/00063

(22) International Filing Date: 14 January 2003 (14.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
24/DEL/2002 15 January 2002 (15.01.2002) IN

(71) Applicant (for all designated States except US): **RANBAXY LABORATORIES LIMITED** [IN/IN]; 19, Nehru Place, 110 019 New Delhi, Delhi (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BAHL, Deepak** [IN/IN]; 73, Unique Apartments, Plot No. 02, Sector - 13, Rohini, 110085 New Delhi, Delhi (IN). **KOCHHAR, Ravi** [IN/IN]; A-118, Ground Floor, Green Woods City, Opp. Sector - 4, 122001 Gurgaon, Haryana (IN). **SHARMA, Puneet** [IN/IN]; A-25, Sector - 15, 201301 Noida, Uttar Pradesh (IN). **NAGAPRASAD, Vishnubhotla** [IN/IN]; 102, Surya Niwas Apartments, Balaji Nagar, 500072 Kukatpally, Hyderabad (IN). **MATHUR, Rajeev, Shanker** [IN/IN]; KD-6,A, Ashok Vihar, Phase-I, New Delhi 110 052 (IN). **MEHTA, Kamal** [IN/IN]; 1-N-30, R.C. Vyas Colony, Bhilwara, Rajasthan (IN).

(74) Common Representative: **RANBAXY LABORATORIES LIMITED**; c/o Deshmukh, Jayadeep, R., 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ACE INHIBITOR(S)

(57) Abstract: The invention provides stable pharmaceutical compositions comprising ACE inhibitor(s) and other pharmaceutically active substances which are susceptible to degradation, as well as processes for the preparation thereof, and methods of treatment involving administration of such compositions.



WO 03/059330 A1

STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING ACE INHIBITOR(S)

Field of the Invention

5 The present invention relates to stable pharmaceutical compositions comprising
ace inhibitor(s), which are susceptible to degradation, and processes for the preparation
thereof.

Background

10 Certain Angiotensin Converting Enzyme (ACE) inhibitors, which are useful as
antihypertensives, are susceptible to certain types of degradation. ACE inhibitors such as
ramipril, quinapril, enalapril, spirapril, lisinopril, benazepril and structurally related drugs
can undergo cyclization via internal nucleophilic attack to form substituted
diketopiperazines. These drugs can also degrade via hydrolysis (of the side-chain ester
15 group) and oxidation, to form products having unwanted coloration. It has been found that
a significant cause of such degradations can be the mechanical stress associated with the
manufacturing process of pharmaceutical composition such as compression. The stability
of pharmaceutical compositions containing ACE inhibitors can also be negatively
influenced by the choice of tableting auxiliaries. In view of the usefulness of ACE
20 inhibitors in treating hypertension, a number of research endeavors have been directed
towards overcoming the inherent instability problem associated with ACE inhibitor-
containing compositions.

For example United States Patent Nos. 4,743,450, 4,830,853, 4,793,998,
international patent application WO 99/62560, European patent EP 468929 disclose
25 stabilization with various agents. United States Patent Nos. 5,151,433 and 5,442,008
disclose polymeric film-formers as protection against stress, as well as the use of buffers.

Thus, either addition of a stabilizer or a polymeric coat on the active ingredient is
believed necessary to stabilize the pharmaceutical composition of ACE inhibitors, which
are susceptible to degradation. However, the addition of such stabilizers can produce
30 unwanted pharmacological effects. Coating the active ingredient is quite cumbersome and
low yielding moreover it requires specialized equipment.

Summary

The applicants of the present invention have discovered a process making the use of the above unnecessary. Active ingredient, for example, an ACE inhibitor, which is susceptible to degradation, is applied as a coat to the core, preferably to a compressed core, thereby avoiding degradation (such as cyclization to diketopiperazine) induced by mechanical stress, which builds up during compression. Such an arrangement also avoids the direct contact of the tableting auxiliaries with the ACE inhibitor, thereby avoiding degradation by any incompatible tablet auxiliaries.

The present invention therefore allows greater flexibility in the choice of tableting auxiliaries. Moreover, as stabilizers are not required, untoward pharmacological effects, which could occur with the addition of such additives, are nullified. The process can be easily scaled up using the conventional tableting and coating equipment.

Therefore, the present invention can provide a stable pharmaceutical composition for oral administration of an ACE inhibitor comprising a core coated with a layer of ACE inhibitor(s) and process for preparation thereof.

Detailed Description

The core of the present invention is preferably a compressed core, which could be inert or may contain a drug other than the ACE inhibitor susceptible to degradation, such as hydrochlorothiazide, piretanide; and dihydropyridines such as felodipine, nitrendipine, nifedipine, lacidipine or other similar drugs. Alternatively the core may be a sugar or starch particle such as non-pareil sugar seeds, or pregelatinized starch. The core can be of any convenient shape, such as an spheroidal shape. The cores can range from about 25 mg to about 1 gram.

The compressed core may comprise diluent and other formulating agents such as binder, disintegrant, lubricant and glidant. The diluent may be, for example, any pharmaceutically acceptable, non-toxic diluent. Particular examples include lactose, dextrose, sucrose, maltose, microcrystalline cellulose, starch, calcium hydrogen phosphate, mannitol and the like.

Binders may be, for example, starch, sugars, gums, low molecular weight hydroxypropyl methylcellulose, hydroxypropylcellulose or the like. Disintegrant may be, for example, croscarmellose sodium, crospovidone, sodium starch glycolate, bentonite, sodium alginate, hydroxypropylmethylcellulose or the like. Lubricants may be, for example, talc, magnesium stearate, calcium stearate, hydrogenated vegetable oils, stearic

acid, sodium stearyl fumarate, sodium benzoate or the like. Glidants may be, for example, colloidal silicon dioxide (aerosil), talc or the like.

The ACE inhibitor layer comprises ACE inhibitor(s), which are susceptible to degradation, including ramipril, spirapril, lisinopril, enalapril, quinapril, benazepril and
5 other structurally related drugs. The process is applicable to other pharmaceutically active agents that are susceptible to mechanical stress-induced or mechanical stress-related degradation. The ACE inhibitor can be micronized, and suspended/dispersed in a solvent to which film forming polymer(s) is added. The film-forming polymer may be, for example, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose,
10 ethylcellulose, cellulose acetate, polyvinylpyrrolidone, gelatin, LustreClear™ (combination of microcrystalline cellulose and carrageenan), combinations of polyvinylalcohol and polyvinylacetate, and the like. The amount of the film forming polymer(s) can be relatively low, to limit the tablet/pellet/beadlet size and the manufacturing effort, but should be sufficient to effectively coat the drug on to the core.
15 The drug to polymer ratio may range from about 1:10 to about 10:1. For example, drug to polymer ratio can be from about 1:2 to about 2:1, or from about 1:1.2 to about 1.2:1, or, for example, about 1:1.

The polymer that is used for binding properties can also protect ACE inhibitors from atmospheric or chemical oxidation and degradation by agents such as atmospheric
20 humidity through, for example, hydrolysis.

The ACE inhibitor layer may optionally contain plasticizers, and is desirably without plasticizers. Stability can be undesirably lessened through the use of plasticizers. Plasticizers which may be excluded from the compositions include polyethyleneglycol, propylene glycol, triethyl citrate, triacetin, dibutylphthalate, diethylphthalate, castor oil,
25 tributyl citrate, glycerol, sorbitol, polysorbates, sorbitan esters and the like. The ACE inhibitor layer may also contain pigments, colorants, antifoaming agents, waxes, monoglycerides, emulsifiers, surfactants or other additives. The layer containing ACE inhibitor or other pharmaceutically active substance can contain such material from about 2% to about 90% by weight of the ACE inhibitor layer, and can also contain film-forming
30 polymer from about 10% to about 98% by weight of the ACE inhibitor layer.

Drug coating solution can be prepared in water, non-aqueous solvents or mixtures thereof. However desirably in water as stability can be lessened through the use of non-aqueous solvents. Solvents that may be excluded are isopropyl alcohol, acetone and methylene chloride .

A seal coat may optionally separate the core and the ace inhibitor layer to completely seal the tableting auxiliaries to come in contact with the ACE inhibitor. Similarly, an outer coat may optionally be given on the ACE inhibitor layer to improve the aesthetic appeal of the tablet and to protect it from the atmospheric humidity. The seal
5 coat and outer coat may have the same composition as the ACE inhibitor layer except the drug, or it may have a different composition. For example, the seal coat may contain other polymers, such as Povidone. The seal coat can be prepared from aqueous dispersion of from about 2% to about 30% by weight of film-forming polymer.

The process of the present invention may be carried out in the following manner.
10 The compressed core can be prepared by conventional techniques such as direct compression, wet granulation and dry granulation.

The ACE inhibitor coating dispersion, suspension or solution can be prepared by adding the active ingredient(s) in a solvent with stirring or other mixing. Film forming polymer(s) and other additives can be added to the active ingredient dispersion with
15 stirring or other mixing. The cores are charged into a coating pan and warmed with air to an outlet-air temperature of, for example, about 30°C-45°C. The ACE inhibitor coating dispersion can be sprayed onto the cores and upon completion, the drug-coated tablets is dried, for example with dry air. Seal coat and outer coat dispersion may be prepared and applied in the similar manner as the ACE inhibitor layer, if required.

20 The coated tablets after air-drying can be packed into containers impervious to water vapor, e.g. blister packs (alu-alu; PVDC, PE, PVC-alu).

The tablets prepared by the present process may also be filed into capsules. The present process may also be applied to the non-pareil seeds or beadlets, which may then be filled in hard gelatin or starch capsules. Such capsules can have better stability as
25 compared to the conventional capsules.

The compositions disclosed herein may be formulated into solid dosage forms for oral administration, such as, for example, tablets, granules, capsules, pills, and the like. In these cases, the medicaments can be prepared by conventional methods, including a therapeutically effective amount of an ACE inhibitor or other pharmaceutically active
30 substance, and optionally but desirably, pharmaceutically acceptable excipients. In addition to the common dosage forms set out, the compositions may also be administered by controlled release means and/or delivery devices, with modifications known to those of ordinary skill in the art.

The compositions may, if desired, be presented in a pack or dispenser device, which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

5 By "therapeutically effective amount" is meant the quantity of a compound or composition according to the invention necessary to prevent, cure or at least partially arrest the symptoms of the disorder and its complications. Amounts effective to achieve this goal will, of course, depend on the severity of the disease and the weight and general state of the patient.

10

Methods of Treatment

The pharmaceutical compositions provided herein can be utilized for various treatment methods, such as those for treating hypertension, either alone or in combination with thiazide diuretics, as well as for use with stable patients who have demonstrated
15 clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction, and also for left ventricular dysfunction and diabetic nephropathy.

The methods include administering to a mammal a therapeutically effective amount of a pharmaceutical composition as described herein.

The administration of pharmaceutical compositions can be by oral or buccal
20 administration,. Other methods of administration will be known to those skilled in the art.

Using the process parameters of the present invention, a convenient, reproducible stable pharmaceutical composition of the ACE inhibitors may be obtained. The present invention is further illustrative by, but is by no-means limited to, the following examples.

25

Examples

Example 1: Preparation of ACE inhibitor formulation

To prepare the tablet cores, in a non-shear blender, microcrystalline cellulose, Pregelatinised starch & Mannitol were mixed and to this mixture sodium stearyl fumarate was added and mixed. The mixture is then compressed to tablets of 100 mg each.

30

To prepare the seal coating solution, hydroxypropylmethylcellulose, hydroxypropylcellulose,(polyethylene glycol, titanium dioxide, and talc) were dispersed in water with stirring and the suspension homogenized.

To prepare the drug coating suspension, ramipril was dispersed in water with stirring and to it hydroxypropylmethylcellulose, hydroxypropylcellulose, (polyethylene glycol, titanium dioxide, and talc) were added. The suspension was homogenized.

The outer-coating solution was prepared similar to the seal coat solution.

5 Tablet cores were placed in the coating pan (Hi-Coater) and heated with warm air to an air outlet temperature of about 30°C-45°C. The seal coating solution was sprayed on the cores. Upon completion the heating was discontinued but the air supply was maintained for about 10 minutes in order to dry the tablets.

10 The coated cores were sprayed with the drug coating solution and air dried maintaining the process parameters as for the seal coat. Similarly, the outer coating solution was then sprayed on the drug coated cores. The tablets were air dried and extracted from the apparatus and packed in suitable pack. The particular amounts of ingredients for various formulations are tabulated in Tables I, II III, IV and V. Tablets prepared according to the ingredients of these tables were prepared according to the
15 process described above.

Table I

INGREDIENT	WEIGHT(mg)
Core	
Mannitol	44.50
Microcrystalline cellulose	43.50
Pregelatinised starch	10.0
Sodium Stearyl Fumarate USNF	2.0
Tablet Weight	100.00
Seal Coat	2
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Target Weight	102.00
Drug layer	
Ramipril	2.5
Film forming Polymer	2.5
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Target Weight	107.00
Outer Coat	2.0
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Total Weight	109.00

Table II

INGREDIENT	WEIGHT(MG)
Core	
Hydrochlorothiazide	25.0
Mannitol	40.0
Dibasic Calcium Phosphate (Anhydrous)	97.855
Starch	19.60
Pregelatinized Starch	4.4
Ferric Oxide (Red)	0.165
Ferric Oxide (Yellow)	0.33
Purified Water	q.s
Pregelatinised Starch	11.00
Magnesium Stearate	1.65
Tablet Weight	200.00
Seal Coat	4.00
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Target Weight	204.00
Drug layer	
Ramipril	5.0
Film forming Polymer	5.0
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Target Weight	214.00
Outer Coat	4.00
Hydroxypropylmethylcellulose(67%)	
Hydroxypropylcellulose(6.7%)	
Polyethylene glycol(12%)	
Titanium dioxide(10%)	
Talc(6.3%)	
Purified water (q.s)	
Total Weight	218.00

Table III

INGREDIENT	WEIGHT(MG)
Core	
Mannitol	44.50
Microcrystalline cellulose	43.50
Pregelatinised starch	10.0
Sodium Stearyl Fumarate USNF	2.0
Tablet Weight	100.00
Seal Coat	2
Hydroxypropylmethylcellulose	
Purified water (q.s)	
Target Weight	102.00
Drug layer	
Ramipril	2.5
Hydroxypropylmethylcellulose	2.5
Purified water (q.s)	q.s
Target Weight	107.00
Outer Coat	2.0
Hydroxypropylmethylcellulose	
Purified water (q.s)	
Total Weight	109.00

Table IV

INGREDIENT	WEIGHT (MG)
Core tablets:	
Mannitol	44.50
Microcrystalline cellulose	44.50
Pregelatinized starch	10.0
Sodium Stearyl Fumarate	1.0
Tablet Weight	100.0
Pre Coat	
Hydroxypropylmethyl cellulose	2.50
Purified water	q.s
Target Weight	102.0
Drug layer	
Ramipril	3.28
Hydroxypropylmethyl cellulose	2.98
Hydroxypropyl Cellulose	0.3
Purified water	q.s
Target Weight	107.25

Table V

Ingredients	Qty(mg)
Core tablets:	
Hydrochlorothiazide	12.50
Mannitol	20.0
Dibasic Calcium Phosphate (anhydrous)	48.928
Maize Starch	9.80
Pregelatinized Starch	2.20
Ferric Oxide (Red)	0.0825
Ferric Oxide (Yellow)	0.165
Purified Water	q.s
Pregelatinised Starch	5.50
Magnesium Stearate	0.825
Tablet Weight	100.00
Pre Coat 1	
Hydroxypropylmethyl cellulose	1.8125
Hydroxypropyl Cellulose	0.1875
Titanium Dioxide	0.50
Purified water	q.s.
Target Weight	102.0
Pre Coat 2	
Hydroxypropylmethyl cellulose	2.5
Purified water	q.s
Target Weight	104.0
Drug layer	
Ramipril	3.28
Hydroxypropylmethyl cellulose	2.98
Hydroxypropyl Cellulose	0.30
Purified water	q.s
Target Weight	109.25

Stability comparisons with conventional tablets having ramipril in the core with or
5 without buffer and marketed ramipril tablets (Delix) of Aventis are shown in Table VI
below.

**TABLE VI: Stability Comparison of 2.5-mg Ramipril Tablets
Prepared by Different Composition/Techniques**

Degradation product	Condition	Ramipril tablets			
		Conventional compressed tablet	Compressed tablet with tris-(hydroxymethyl) aminomethane buffer	Tablets prepared as per example 1	Delix marketed ramipril tablets of Aventis
Diketopiperazine (%)	Initial	1.91	0.048	0.262	
	60°C/2 weeks	18.48	4.61	4.42	5.91
Total Related Substances (%)	Initial	1.95	0.072	0.47	
	60°C/2 weeks	19.22	7.26	4.59	

The stability of tablets prepared according to Tables IV and V was determined at 40°C / 75% relative humidity for a period of 6 months. The results of the same are summarized in Table VII and VIII below.

**Table VII: Stability Data of Ramipril Tablets Prepared as per Table IV
for 6 Months Stored at 40°C/75% Relative Humidity**

	Initial	1 month	2 months	3 months	6 months
Diketopiperazine (%)	0.13	1.26	1.92	2.88	4.92
Total impurities (%)	0.16	1.48	2.06	3.19	5.51
Assay (%w/w)	103.2	101.6	99.3	98.1	95.4

Table VIII: Stability Data of Ramipril+Hydrochlorothiazide Tablets Prepared as per Table V for 6 Months Stored at 40°C/75% Relative Humidity

	Initial	1 month	2 months	3 months	6 months
Diketopiperazine (%)	0.265	1.448	2.295	3.481	6.778
Impurities of Hydrochlorothiazide (%)	0.407	0.436	0.531	0.701	0.829
Total Impurities (%)	1.289	2.573	3.094	4.338	7.159
Assay (%w/w)					
Ramipril Assay (%)	103.8	102.6	100.4	97.2	93.8
Hydrochlorothiazide assay (%)	101.2	101.3	100.8	100.6	99.2

- 5 The data clearly show that the tablets prepared by the processes described herein provide the most stable tablets.

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

CLAIMS:

- 1 1. A stable pharmaceutical composition for oral administration of ACE inhibitor(s)
2 comprising a core coated with a layer of ACE inhibitor(s).
- 1 2. The composition of claim 1, wherein the said layer is without plasticizer.
- 1 3. The composition of claim 1, wherein the ACE inhibitor is selected from the group
2 consisting of ramipril, quinapril, enalapril, spirapril, lisinopril, and benazepril.
- 1 4. The composition of claim 1, wherein the layer of ACE inhibitor(s) comprises film
2 forming polymer.
- 1 5. The composition of claim 4, wherein the film forming polymer is selected from the
2 group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose,
3 hydroxyethylcellulose, ethylcellulose, cellulose acetate, polyvinylpyrrolidone, gelatin,
4 a combination of microcrystalline cellulose and carrageenan, and a combination of
5 polyvinylalcohol and polyvinylacetate.
- 1 6. The composition of claim 4, wherein the layer of ACE inhibitor(s) further comprises
2 other additives.
- 1 7. The composition of claim 1, wherein the core is a compressed tablet.
- 1 8. The composition of claim 1, wherein the core comprises a sugar sphere or nonpareil
2 seeds.
- 1 9. The composition of claim 7 or 8, wherein compressed tablets, sugar spheres or
2 nonpareil seeds are filled into hard gelatin capsules.
- 1 10. The composition of claim 1, wherein the core is inert.
- 2 11. The composition of claim 1, wherein the core has a pharmaceutically active substance
3 other than the one which is susceptible to degradation by mechanical stress.
- 1 12. The composition of claim 11 wherein the pharmaceutically active substance is selected
2 from the group consisting of hydrochlorothiazide, pirtanide, and dihydropyridines

- 1 13. The composition of claim 12, wherein the dihydropyridines are selected from the
2 group consisting of felodipine, nitrendipine, nifedipine and lacidipine.
- 1 14. A stable pharmaceutical composition for oral administration of pharmaceutically
2 active substance, comprising a core coated with a layer of pharmaceutically active
3 substance, wherein the pharmaceutically active substance is susceptible to degradation
4 by mechanical stress.
- 5 15. The composition of claim 1, wherein a seal coat separates the core and the layer of
6 ACE inhibitor(s).
- 1 16. The composition of claim 1, wherein the layer of ACE inhibitor(s) is further
2 surrounded with an outer coat.
- 1 17. A process for the preparation of a stable pharmaceutical composition for oral
2 administration of ACE inhibitor(s) comprising disposing a layer of an ACE inhibitor
3 dispersion, suspension or solution onto a core.
- 1 18. The process of claim 17, wherein the layer is disposed as a coating dispersion.
- 1 19. The process of claim 18, wherein the coating dispersion is made in aqueous solvent.
- 1 20. The process of claim 17, wherein the dispersion is sprayed on the cores.
- 1 21. A method of treating a disorder selected from the group consisting of hypertension,
2 congestive heart failure left ventricular dysfunction and diabetic nephropathy, the
3 method comprising administration of a therapeutically effective amount of the
4 pharmaceutical composition of claim 1 to a patient suffering from such disorder.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 03/00063

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/24 A61K38/55 A61K31/401

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EPO-Internal, PAJ, COMPENDEX, BIOSIS, MEDLINE, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 086 919 A (BAUER BRIGITTE ET AL) 11 July 2000 (2000-07-11) claims 1-5,14,21; example 1 ---	1-21
X	WO 01 51037 A (PHOENIX U S A INC LAB (US)) 19 July 2001 (2001-07-19) page 3, line 27 -page 4, line 24 page 26, line 18 -page 27, line 26 page 28, line 3 - line 7; claims 1,23-25; example 1 ---	1-21
X	EP 0 309 051 A (MERCK & CO INC) 29 March 1989 (1989-03-29) claims 1,7-9; example 4 ---	1-21
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

17 April 2003

Date of mailing of the international search report

28/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Leutner, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 03/00063

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 800 084 A (ZERBE HORST) 24 January 1989 (1989-01-24) column 2, line 46 - line 64; claim 1; example 1 -----	1-21
X	US 5 158 777 A (ABRAMOWITZ ROBERT ET AL) 27 October 1992 (1992-10-27) column 4, line 9 - line 25; claims 6,7; example 3 -----	1-21
X	US 6 004 582 A (MAYORGA JORGE ET AL) 21 December 1999 (1999-12-21) claims 1,10,14; examples 5,6 -----	1-20

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: —
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 21 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box I.2

Present claim 14 relates to 'pharmaceutically active substances, wherein the pharmaceutically active substance is susceptible to degradation by mechanical stress'. This expression lacks clarity and conciseness because it is not well established and recognized in the prior art which kind of pharmaceutically active substances fall into the scope of claim 14. Thus, the expression does not enable the skilled person to establish a complete list of compounds that fall into the scope of claim 14.

Moreover, claim 14 refers to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed (ACE inhibitors). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Also the term 'mechanical stress' lacks clarity (Article 6 PCT) since it is not clear which kind of mechanical stress is meant (e.g., scratching or scraping off, chewing, pressure). Moreover, it is also not clear which kind of layer is used. Claim 14 could be read as if the layer should act as a protective layer by preventing the degradation of the susceptible substance.

Thus, their intended meaning is not obvious without any further explanation.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds mentioned in claims 1 and 3 and in the description at page 3, line 4-5, and in tables I-VII (ramipril).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Internat^l Application No

PCT/IB 03/00063

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6086919	A	11-07-2000	AT 217187 T	15-05-2002
			AU 695865 B2	27-08-1998
			AU 3402995 A	27-03-1996
			CA 2174338 A1	14-03-1996
			CN 1134665 A	30-10-1996
			CZ 9601173 A3	11-09-1996
			DE 69526640 D1	13-06-2002
			DE 69526640 T2	07-11-2002
			DE 726766 T1	30-01-1997
			DK 726766 T3	22-07-2002
			EE 9600072 A	16-12-1996
			EP 0726766 A1	21-08-1996
			ES 2091173 T1	01-11-1996
			FI 961863 A	02-05-1996
			GR 96300055 T1	31-10-1996
			HK 1001811 A1	27-09-2002
			HU 76049 A2	30-06-1997
			JP 9504806 T	13-05-1997
			NO 961726 A	29-04-1996
			NZ 292298 A	26-02-1998
			NZ 329556 A	28-07-2000
			PL 314084 A1	19-08-1996
			PT 726766 T	31-10-2002
			RU 2184563 C2	10-07-2002
			WO 9607400 A1	14-03-1996
			SI 726766 T1	31-10-2002
			SK 55896 A3	05-03-1997
			TR 960186 A2	21-06-1996
			ZA 9507043 A	04-03-1996
WO 0151037	A	19-07-2001	US 2002006430 A1	17-01-2002
			AU 2770901 A	24-07-2001
			WO 0151037 A1	19-07-2001
EP 0309051	A	29-03-1989	US 4880631 A	14-11-1989
			US 4886668 A	12-12-1989
			AT 73322 T	15-03-1992
			AU 2277388 A	06-04-1989
			CA 1320885 A1	03-08-1993
			DE 3869032 D1	16-04-1992
			DK 529188 A	18-05-1989
			EP 0309051 A1	29-03-1989
			ES 2039275 T3	16-09-1993
			GR 3004364 T3	31-03-1993
			HK 47493 A	21-05-1993
			IE 62747 B1	22-02-1995
			IL 87756 A	01-12-1992
			JP 1128927 A	22-05-1989
			JP 2610316 B2	14-05-1997
			KR 9707190 B1	07-05-1997
			LV 5786 A4	20-02-1997
			MX 9203052 A1	01-07-1992
			NZ 226179 A	26-04-1991
			PT 88566 A ,B	01-10-1988
			SG 16393 G	16-04-1993
			ZA 8807010 A	27-09-1989
US 4800084	A	24-01-1989	DE 3403329 A1	01-08-1985

INTERNATIONAL SEARCH REPORT

International application No

PCT/ID J3/00063

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4800084	A	AT 62130 T DE 3582360 D1 EP 0163000 A2	15-04-1991 08-05-1991 04-12-1985
US 5158777	A	27-10-1992 NONE	
US 6004582	A	21-12-1999 AU 7706598 A BR 9802144 A CA 2261787 A1 CN 1228020 T EP 0914098 A1 WO 9853802 A1 JP 2000516637 T	30-12-1998 25-05-1999 03-12-1998 08-09-1999 12-05-1999 03-12-1998 12-12-2000